Table 3. Resistance patterns with non-nucleoside reverse transcriptase inhibitor mutations (NNRTI) analyzed on the Stanford database (n = 41).
| Mutational pattern | Drug resistance profile | ||||
|---|---|---|---|---|---|
| No (%) | EFV& | NVP¶ | ETRš | RPVμ | |
| ART-Experienced (n = 24) | |||||
| A98G-K103N-Y181C | 1 (2.4) | HLR* | HLR | IR† | IR |
| K103N-Y181C | 1 (2.4) | HLR | HLR | IR | IR |
| A90G-G190A-K103N-V108I | 1 (2.4) | HLR | HLR | LLRø | LLR |
| K101E-V108I-Y181C | 1 (2.4) | HLR | HLR | LLR | LLR |
| G190A-K101E | 1 (2.4) | HLR | HLR | LLR | LLR |
| K103N-V179E | 1 (2.4) | HLR | HLR | PLR‡ | PLR |
| A98G-K103N-V108I | 1 (2.4) | HLR | HLR | S# | S |
| V106A-P225H | 1 (2.4) | HLR | HLR | S | S |
| K103N only (or with P225H or V106A) | 4 (9.8) | HLR | HLR | S | S |
| Y181C only (or with V108I) | 4 (9.8) | IR | HLR | IR | IR |
| G190A-K103N-K101E/Q | 2 (4.9) | IR | HLR | LLR | LLR |
| G190A | 1 (2.4) | IR | HLR | PLR | PLR |
| V106A | 1 (2.4) | IR | HLR | S | S |
| V179E | 2 (4.9) | PLR | PLR | PLR | PLR |
| V108I | 1 (2.4) | PLR | LLR | S | S |
| K101Q | 1 (2.4) | S | S | S | S |
| ART-Naïve (n = 17) | |||||
| G190A-Y181C | 1 (2.4) | HLR | HLR | HLR | HLR |
| G190A-K101E | 1 (2.4) | HLR | HLR | LLR | LLR |
| K103N | 2 (4.9) | HLR | HLR | S | S |
| Y181C | 2 (4.9) | IR | HLR | IR | IR |
| P225H | 1 (2.4) | IR | IR | S | S |
| V179E | 4 (9.8) | PLR | PLR | PLR | PLR |
| V108I | 1 (2.4) | PLR | LLR | S | S |
| V106, V118I | 1 (2.4) | S | PLR | PLR | PLR |
| E138A | 2 (4.9) | S | S | PLR | LLR |
| V90I | 1 (2.4) | S | S | S | S |
| K101Q | 1 (2.4) | S | S | S | S |
&EFV: Efavirenz
šETR: Etravirine
¶ NVP: Nevirapine
μRPV: Rilpivirine
#S: susceptible
* HLR: High-level resistance
†IR: Intermediate resistance
øLLR: Low-level resistance
‡PLR: Potential low-level resistance